Storia in 2 fonti

Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions - Cigna Group (NYSE:CI)

Cigna beat second-quarter earnings and revenue estimates, raised its 2026 profit outlook and said GLP-1 utilization growth is moderating.

Raccontata da

fiercehealthcare.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 h fa

Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions - Cigna Group (NYSE:CI)

Cigna beat second-quarter earnings and revenue estimates, raised its 2026 profit outlook and said GLP-1 utilization growth is moderating.

originale

fiercehealthcare.com10 h fa

Cigna boosts outlook as it posts Q2 beat on earnings, revenue

Cigna posts Q2 beat: $1.7B profit (+13%), $71.7B revenue (+6.7%), upgrades EPS guidance to $30.45. AI-personalization in customer care and Evernorth platform (+6%) offset medical cost pressure; validates tech-stack as payer competitive moat.

Leggi questa versione →

Timeline cronologica

giovedì 30 luglio 2026·fiercehealthcare.com
Cigna boosts outlook as it posts Q2 beat on earnings, revenue
Cigna is raising its outlook for the year after beating the Street on both earnings and revenue in the second quarter of 2026. | Cigna is raising its outlook for the year after…
giovedì 30 luglio 2026·benzinga.com
Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions - Cigna Group (NYSE:CI)
Cigna beat second-quarter earnings and revenue estimates, raised its 2026 profit outlook and said GLP-1 utilization growth is moderating.